RecruitingPhase 1Phase 2NCT07220616

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

Sponsor

Daiichi Sankyo

Enrollment

420 participants

Start Date

Jan 16, 2026

Study Type

INTERVENTIONAL

Conditions

B-cell Non Hodgkin Lymphoma Hematological Malignancies

Summary

This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Combination drug, Combination drug, and others for people with b-cell non hodgkin lymphoma and hematological malignancies. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDS3790a

Administered as specified in the protocol

DRUGCombination drug

Administered as specified in the protocol

DRUGCombination drug

Administered as specified in the protocol

Locations(6)

Research Site

New York, New York, United States

Research Site

Lille, France

Research Site

Pierre-Bénite, France

Research Site

Nagoya, Japan

Research Site

Tokyo, Japan

Research Site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07220616

Related Trials

A Study of ARC-02 in B-cell NHL

NCT0769160629 locations

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

NCT0536565913 locations

Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant

NCT077091951 location

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT0656403864 locations

To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers

NCT077199462 locations